The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt
October 23, 2022 updated by: Mahmoud Samy Abdallah, Sadat City University
This study aimed at study the clinical and pathological criteria of Hepatocellular carcinoma to keep with new challenging in diagnosis and morpho-molecular classifications
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
530
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Menoufia
-
Shibīn Al Kawm, Menoufia, Egypt, 32511
- National Liver Intitute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
HCC cases from a single tertiary center eligible for pathological analysis as a primary tool
Description
Inclusion Criteria:
- All pathologically proven Hepatocellular Carcinoma
Exclusion Criteria:
- Other malignant tumors than Hepatocellular Carcinoma
- Benign tumor
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinicopathological factors of Hepatocellular Carcinoma
Time Frame: 10 years
|
Serum alpha-fetoprotein (AFP) level
|
10 years
|
|
Clinicopathological factors of Hepatocellular Carcinoma
Time Frame: 10 years
|
Tumor size and focality
|
10 years
|
|
Clinicopathological factors of Hepatocellular Carcinoma
Time Frame: 10 years
|
Vascular invasion
|
10 years
|
|
Clinicopathological factors of Hepatocellular Carcinoma
Time Frame: 10 years
|
Pathologic stage and grade
|
10 years
|
|
Clinicopathological factors of Hepatocellular Carcinoma
Time Frame: 10 years
|
The reserve of background liver
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Actual)
October 31, 2021
Study Completion (Actual)
July 31, 2022
Study Registration Dates
First Submitted
September 2, 2021
First Submitted That Met QC Criteria
September 14, 2021
First Posted (Actual)
September 16, 2021
Study Record Updates
Last Update Posted (Actual)
October 25, 2022
Last Update Submitted That Met QC Criteria
October 23, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00246/2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
sharing will be by website or google after paper publication
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.